In summary, we demonstrate that DHODH inhibition in patients with RRMS was associated with a lower in vivo proliferation of CD8 T cells with reduced proinflammatory properties 12 months after treatment. The gene discussed is DHODH; the disease is relapsing-remitting multiple sclerosis.